Background:
The incidence of Kawasaki disease has been increasing since it was first reported by Tomisaku Kawsasaki in 1967. Among complications of the condition, the formation of coronary artery aneurysms is the most important. In particular, giant aneurysms with diameters that exceed 8 mm are likely to not regress and result in serious complications, such as acute myocardial infarction. Objectives: To understand the long-term course of patients with giant aneurysms and Kawasaki disease as well as to consider the cause of aneurysm formation and its appropriate treatment. Methods: We retrospectively studied the long-term course of 12 cases of giant coronary artery aneurysms accompanied with Kawasaki disease, which were being followed at Shiga University of Medical Science Hospital, Omihachiman Community Medical Center, and Nagahama Red Cross Hospital. These are three major facilities in Shiga prefecture of Japan, whose population is 1.4 million, comprising 200,000 children. Results: Ten male and two female patients were included. The average current age was 16.8 years, the median age was 14.3 (10.7-18.9) years, and 5 cases were of adults. The average age at the time of onset was 3.5 years, the median age was 3.7 years (1.8 -4.4), and all experienced onset between 1 and 5 years of age. The mean period from onset to treatment start was 6.7 days (median 5.0 (4.3-8.3)), but the average period until fever declined was 16.0 days and only three patients' temperature was reduced in 10 days. Aneurysm formation occurred at 14.1 days on average (median 12 (10) (11) (12) (13) (14) (15) (16) (17) ). The average size of the maximum coronary artery aneurysm at onset was 11.3 mm, and the median size was 9.5 mm (8.8 mm -13.8 mm).The average and median follow-up periods were 13.2 years and 11.7 years (5.4-13.4), respectively. The number of patients received steroid therapy was four, and all their onset was after 2006. None received infliximab or underwent plasmapheresis. During the course of the condition, all patients underwent multiple centripetal echocardiography. Among all cases, 7 underwent coronary angiography CT, 10 underwent myocardial scintigraphy. All 12 patients underwent cardiac catheterization and the total number of underwent cardiac catheterization for them was thirty-one. Two adult patients had a history of acute myocardial infarction and had undergone cardiac bypass surgery. Through this survey, we found that 9 cases developed giant coronary artery aneurysm between 1983 and 2007, and 3 cases between 2012 and 2015 used prednisolone. Conclusions: All patients are currently receiving anticoagulant therapy and undergoing diagnostic imaging. In our prefecture, the incidence of giant coronary artery aneurysm accompanied with Kawasaki disease has been decreasing gradually. From 2007 to 2012, in which high dose gamma globulin therapy (2g/kg) has become commonly underwent for Kawasaki disease in Japan, there were no giant aneurysm formation in our hospitals. Three patients in whom giant aneurysms developed between 2012 and 2015 were taking oral prednisolone, thereby suggesting a relationship between prednisolone and giant aneurysm formation. Background: Behçet Disease (BD) is rarely reported in children. It a systemic inflammatory condition characterised by autoinflammatory and vasculitic clinical features including recurrent oral aphthosis, genital ulceration, skin, eye, neurological and vascular inflammation, which is most commonly diagnosed between 20-40 years of age. It is unclear how many adult patients with BD have the onset of symptoms during childhood. Objectives: The aim of our study was to investigate the age of symptom onset in a large cohort of adult patients with BD. Methods: Since 2012, the Behçet Syndrome National Centre of Excellence, Birmingham and Midland Eye Centre, has used a multidisciplinary approach aiming to shorten time to diagnosis of BD, reduce blindness and morbidity, improve knowledge and ensure equity in access to biological therapies. Patient demographic and disease information, including patient recalled age at symptom onset, symptom sequence, documented clinical signs, treatment and outcome data are maintained in a secure web-based clinical data archive. For this study, the database was interrogated to determine patient age at recalled onset of the first BD symptoms, the sequence in which symptoms appeared and whether the ISG classification criteria for the diagnosis of BD were fulfilled before the age of 16 years. Background: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatologic illness and can lead to significant disability. Complementary and alternative treatments are commonly practiced by families of patients with JIA, and >40% of patients with chronic arthritis seek dietary changes after their diagnosis. Dietary intervention studies in adults with rheumatoid arthritis showed moderate improvement in joint symptoms. Dietary supplements of omega-3 fatty acids have been tested in children with chronic arthritis and found to be associated with less NSAID use and lower serum IL-1 and TNF levels. There is an increasing need to understand if there is a role for dietary therapy in chronic arthritis. Objectives: We aimed to evaluate the prevalence of special diets and the perception of the effectiveness of these diets on arthritis in JIA. We also assessed the interest of dietary interventions and perceived barriers. Methods: An online survey was designed through a REDCap database capturing demographic information, self-or parent-initiated special dietary interventions and self-or parent-observing effects on joint symptoms, willingness to participate in a dietary intervention study. The survey link was posted on social media websites and distributed by the Arthritis Foundation. Descriptive statistical analyses were performed. Results: A total of 265 responses were received from adult patients who had JIA and parents of children with JIA. We excluded 14 patients with inflammatory bowel disease or celiac disease-related arthritis and 24 responders with incomplete answers. Demographic and JIA characteristics of adult and pediatric patients are listed in Table 1 . Ninety patients (63 children with JIA, 27 adults with history of JIA) had tried a special diet for arthritis. The top three special diets reported by parents included a gluten-free diet (62%), an anti-inflammatory diet (53%), and a lactose-free diet (26%). There were similar clinical responses among the three diets (Figure 1 ). Twenty-five to thirty percent reported no change in joint symptoms whereas 20-30% reported improved pain or joint swelling. Sixty-one (34%) parents were willing to participate in a 3-month dietary intervention study and 78 (44%) parents answered "it depends". Conclusions: This is the first report of the family/patient perspective of the role of dietary intervention on JIA. Almost half of the affected patients attempted special diets, and many reported improvement in symptoms. Future interventional studies with objective outcome measurements are needed to validate these reports. Other orphan diseases Background: IgG4-related disease (IgG4-RD) is a systemic fibro-inflammatory disorder characterized by fibrotic lesions infiltrated by IgG4 positive plasma cells (1) . The prompt clinical responses obtained after B cell depletion with rituximab in IgG4-RD patients suggest that B lymphocytes drive the pathogenesis of this condition and sustain disease activity (2). This conclusion, however, requires further confirmation because IgG4-RD responds also to non-B cell depleting therapies such as glucocorticoids and methotrexate Objectives: To evaluate the effects of glucocorticoids and methotrexate-based therapeutic regimens on B lymphocyte subpopulations in patients with IgG4-RD. Methods: Sixteen patients with active IgG4-RD were studied. FACS analysis was performed on peripheral blood in order to identify the following B cell subpopulations: total B cells (CD19+CD20-and CD19+CD20+ cells), circulating plasmablasts (CD19+CD20-CD27+CD38++ cells), naïve B cells (CD19+CD20+CD27-CD38+ cells), memory B cells (CD19+CD20-CD27+CD38-cells), circulating plasma cells (CD38+CD138+ cells). Disease activity was assessed by means of the IgG4-RD responder index (IgG4-RD RI). Flow cytometry was performed at baseline and after six months of immunosuppressive therapy with glucocorticoids (0.6-1mg/kg/day) and/or methotrexate (10-20mg/week). 16 sex and age matched healthy subjects were used as controls. Results: At baseline, circulating plasmablasts were expanded in IgG4-RD patients (median 3780 cell/mL; range 330-9300) compared to controls (median 280 cell/mL; range 0-1000) (p<0.05); total B cells (median 133000 cell/mL; range 34000-569000) and naïve B cells (median 13080 cell/mL; range 1970-64270) were reduced in IgG4-RD patients compared to controls (median 280 cell/mL; range 194-330; and median 54020 cell/mL; range 21050-106780, respectively) (p<0.05). No circulating plasma cells were detected in healthy controls. No differences in memory B cells were observed (p>0.05). Circulating plasmablasts but not other B cell subsets positively correlated with serum IgG4 levels, number of organ involved, and IgG4-RD RI (p<0.05). At six months follow-up, the median IgG4-RD RI decreased from 9 to 2. Circulating plasmablasts, circulating plasma cells, and naïve B cells counts decreased in all patients together with disease improvement (p=0.0002, 0.0002 and 0.025 compared to baseline values, respectively); total B cells and memory B cells were unaffected by immunosuppressive therapy. 
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